Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gatifloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Gatifloxacin SCHEMBL30910969 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (R)-Gatifloxacin SCHEMBL5670068 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL22592 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL2224369 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL29356306 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL1380256 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL1380257 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL3565686 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| (S)-Gatifloxacin SCHEMBL1046589 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 | |
| Gatifloxacin SCHEMBL29765369 | 0.99 | KDM4E (0.98) | KDM4EALDH1A1HPGDKCNH2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 28002 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120754262-B | Nucleic acid delivery vector and preparation method and application thereof | Shenzhen Jinlin Biotechnology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| US-12624057-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2026-05-12 | — | — | US | claimed |
| CN-122017062-A | HPLC-MS/MS-based detection method for concentration of 8 two-wire antitubercular drugs | 杭州度安医学检验实验室有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| CN-1300216-A | Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts of hydrates | GRELUNTHAL GMBH (DE) | 2001-06-20 | — | — | CN | claimed |
| EP-1077703-A1 | ORAL MEDICINAL PREPARATIONS WITH REPRODUCIBLE RELEASE OF THE ACTIVE INGREDIENT GATIFLOXACIN OR ITS PHARMACEUTICALLY SUITABLE SALTS OR HYDRATES | Grünenthal GmbH (DE) | 2001-02-28 | — | — | EP | claimed |
| CN-1275081-A | Aqueous liquid preparations | SENJU PHARMA CO (JP) | 2000-11-29 | — | — | CN | claimed |
| EP-1025846-A1 | AQUEOUS LIQUID PREPARATIONS | Senju Pharmaceutical Co., Ltd. (JP) | 2000-08-09 | — | — | EP | claimed |
| WO-2000012048-A2 | CARBAPENEM ANTIBACTERIAL COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2000-03-09 | — | — | WO | claimed |
| WO-1999058129-A1 | ORAL MEDICINAL PREPARATIONS WITH REPRODUCIBLE RELEASE OF THE ACTIVE INGREDIENT GATIFLOXACIN OR ITS PHARMACEUTICALLY SUITABLE SALTS OR HYDRATES | Grünenthal GmbH (DE) | 1999-11-18 | — | — | WO | claimed |
| US-5880283-A | Gatifloxacin hydrate | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1999-03-09 | — | — | US | claimed |
| EP-0805156-A1 | 8-ALKOXYQUINOLONECARBOXYLIC ACID HYDRATE WITH EXCELLENT STABILITY AND PROCESS FOR PRODUCING THE SAME | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1997-11-05 | — | — | EP | claimed |
| US-4980470-A | 8-alkoxyquinolonecarboxylic acid and salts thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-12-25 | — | — | US | claimed |
| EP-0241206-A2 | Quinoline-3-carboxylic acid derivatives, their preparation and use | Sankyo Company Limited (JP) | 1987-10-14 | — | — | EP | claimed |